Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022
April 14, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022 16:05 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...
Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership
April 05, 2022 07:00 ET
|
Plus Therapeutics Inc.
Companies collaborate to design innovative registrational trial of 186RNL for recurrent glioblastoma Proprietary Synthetic Control ArmⓇ solution intended to enhance enrollment and reduce costs ...
Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
March 22, 2022 07:00 ET
|
Plus Therapeutics Inc.
ReSPECT-LM trial to evaluate safety/tolerability and identify MTD/MFD in three cohorts Rhenium-186 NanoLiposome (186RNL) now in two active U.S. clinical trials for CNS cancers AUSTIN, Texas, March ...
Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference
March 03, 2022 07:30 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted...
Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
February 24, 2022 16:05 ET
|
Plus Therapeutics Inc.
Expanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management to host conference...
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial
February 22, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
February 18, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present at BIO CEO & Investor Conference
February 07, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...